Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2014

Open Access 01-12-2014 | Research article

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

Authors: Claudia Marchetti, Francesca De Felice, Innocenza Palaia, Giorgia Perniola, Angela Musella, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici

Published in: BMC Women's Health | Issue 1/2014

Login to get access

Abstract

Background

Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated risk of developing ovarian cancer. The aim of the meta-analysis is to clarify the role of risk-reducing salpingo-oophorectomy (RRSO) to reduce ovarian cancer risk and mortality in women with BRCA 1 and BRCA 2 mutation carriers.

Methods

Pubmed, Medline and Scopus were searched to select English-language articles. Two investigators independently extracted characteristics and results of selected studies. Articles were included only if prospective and if absolute numbers of ovarian cancer and death events were available or derivable from the test. Pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using fixed effects model.

Results

Meta-analysis of 3 prospective studies demonstrated a significant risk reduction of ovarian cancer with RRSO in BRCA 1 and BRCA 2 mutation carriers, as well as benefit in all-causes mortality incidence.

Conclusions

It may be justified to recommend RRSO to reduce ovarian cancer risk and all-causes mortality in women with a mutation in BRCA 1 and BRCA 2.
Appendix
Available only for authorised users
Literature
1.
Bougie O, Weberpals JI: Clinical considerations of BRCA1- and BRCA2- mutation carriers: a review. Int J Surg Oncol. 2011, 2011: 374012.PubMedPubMedCentral
2.
King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003, 302: 643-646. 10.1126/science.1088759.CrossRefPubMed
3.
Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2009), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. [released April 2012 based on November 2011 submission]. Available at: www.​seer.​cancer.​gov.
4.
5.
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006, 296 (2): 185-192. 10.1001/jama.296.2.185.CrossRefPubMed
6.
Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, et al: Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014, 32 (15): 1547-1553. 10.1200/JCO.2013.53.2820.CrossRefPubMedPubMedCentral
7.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007, 8: 16-10.1186/1745-6215-8-16.CrossRefPubMedPubMedCentral
8.
9.
Egger M, Davey SG, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BJM. 1997, 315 (7109): 629-634. 10.1136/bmj.315.7109.629.CrossRef
10.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50 (4): 1008-1101. 10.2307/2533446.CrossRef
11.
Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst. 2003, 95 (14): 1072-1078. 10.1093/jnci/95.14.1072.CrossRefPubMed
12.
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002, 346 (21): 1616-1622. 10.1056/NEJMoa012158.CrossRefPubMed
13.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010, 304 (9): 967-975. 10.1001/jama.2010.1237.CrossRefPubMedPubMedCentral
14.
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008, 26 (8): 1331-1337. 10.1200/JCO.2007.13.9626.CrossRefPubMedPubMedCentral
15.
Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009, 101 (2): 80-87. 10.1093/jnci/djn442.CrossRefPubMedPubMedCentral
16.
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K: Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002, 8: 3776-3781.PubMed
17.
Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ: Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006, 7 (10): 821-828. 10.1016/S1470-2045(06)70869-5.CrossRefPubMed
18.
Metcalfe KA, Ghadirian P, Rosen B, Foulkes W, Kim-Sing C, Eisen A, Ainsworth P, Horsman D, Maugard C, Provencher D, Robideaux A, Gilchrist D, Chudley A, Lemire EG, Armel S, Finch A, Sun P, Narod SA: Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med. 2007, 2: 92-98.
19.
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008, 122: 2017-2022. 10.1002/ijc.23340.CrossRefPubMedPubMedCentral
20.
Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK: Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005, 23: 6890-6898. 10.1200/JCO.2005.02.626.CrossRefPubMed
21.
Finch A, Evans G, Narod SA: BRCA carriers, prophylactic salpingooophorectomy and menopause: clinical management considerations and recommendations. Womens Health. 2012, 5: 543-555.
22.
Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB: Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause. 2014, 21 (7): 763-768. 10.1097/GME.0000000000000126.CrossRefPubMed
Metadata
Title
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers
Authors
Claudia Marchetti
Francesca De Felice
Innocenza Palaia
Giorgia Perniola
Angela Musella
Daniela Musio
Ludovico Muzii
Vincenzo Tombolini
Pierluigi Benedetti Panici
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2014
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-014-0150-5

Other articles of this Issue 1/2014

BMC Women's Health 1/2014 Go to the issue

Research article

Relationship between menopause and health-related quality of life in middle-aged Chinese women: a cross-sectional study

Research article

Health related quality of life in patients in dialysis after renal graft loss and effect of gender

Research article

Severe morbidities associated with induced abortions among misoprostol users and non-users in a tertiary public hospital in Ghana

Editorial

The CROWN Initiative: journal editors invite researchers to develop core outcomes in women’s health

Research article

Association between physical activity and menopausal symptoms in perimenopausal women

Study protocol

Hysteropexy in the treatment of uterine prolapse stage 2 or higher: a multicenter randomized controlled non-inferiority trial comparing laparoscopic sacrohysteropexy with vaginal sacrospinous hysteropexy (LAVA-trial, study protocol)